. PCR ribotyping results demonstrating carriage of identical epidemic Clostridium difficile isolates in stool samples of a peripartum woman with recurrent C. difficile infection and her asymptomatic baby. The epidemic control strain and the isolates obtained from the mother and the baby had PCR amplification results positive for binary toxin gene cdtB and partial deletions of the tcdC gene, whereas the nonepidemic control strain did not. To the Editor-Recent outbreaks of Clostridium difficile-associated disease (CDAD) have been attributed to the emergence of an epidemic strain, termed North American PFGE type 1, which produces binary toxin and has a genetic deletion associated with increased toxin production [1] . There have also been recent reports of severe CDAD in low-risk populations, including peripartum women [2] . In 2 cases, peripartum women possibly transmitted C. difficile to their children [2] . We report a case of recurrent CDAD due to the epidemic strain in a peripartum woman whose baby was an asymptomatic carrier of the same strain.
A 19-year-old previously healthy woman delivered a baby and was discharged from the hospital 2 days later. She had received azithromycin 6 months earlier but had received no other antibiotics. Diarrhea developed 10 days after delivery, and CDAD was diagnosed on the basis of a positive toxin enzyme immunoassay result. The patient's symptoms resolved with oral metronidazole, but she subsequently developed 3 recurrences that were treated with oral vancomycin for 10 days, vancomycin taper for 6 weeks, and oral nitazoxanide for 10 days, respectively. Her baby remained healthy with no diarrhea.
To investigate whether the baby could be a potential source for re-exposure of the mother, we cultured stool samples obtained from the mother at the time of her third relapse and obtained concurrently from the baby. C. difficile isolates were tested for in vitro cytotoxin production and were analyzed for binary toxin gene cdtB and partial deletions of the tcdC gene, as described elsewhere [3] . Molecular typing was performed using PCR ribotyping [4] . To assess whether the epidemic strain might be circulating on the newborn unit, we performed cultures and typing of stool samples obtained from healthy babies on the neonatal unit and from environmental sites.
Both the mother and the baby carried the epidemic C. difficile strain (figure 1). The baby's stool sample contained 6 log 10 colony-forming units of C. difficile per g of stool. The mother was instructed to perform careful hand washing after changing diapers and to use 10% bleach for surface disinfection. No further recurrences occurred. On the healthy-baby unit, 10 (50%) of 20 stool samples obtained from newborns and 4 (17%) of 24 environmental cultures were positive for C. difficile, but none of the isolates were of the epidemic strain.
In summary, we report a case of recurrent CDAD attributable to an epidemic strain in a peripartum woman whose baby carried the same strain asymptomatically. It is not known whether the mother acquired the strain and transmitted it to her baby or vice versa, and the original source of the epidemic strain is unclear. Nevertheless, it is plausible that the baby contributed to the mother's recurrences by providing a source of repeated exposure to C. difficile during activities such as diaper changing. McFarland et al. [5] previously reported 5 cases of recurrent CDAD in peripartum women; in 2 cases, the babies carried the same strain as their mothers. CDAD should be considered to be a possible cause of diarrhea in peripartum women, even in the absence of recent antibiotic therapy. Asymptomatically colonized babies have the potential to serve as reservoirs for transmission of North American PFGE type 1 strains. 
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Initial Hospitalization and Adherence to Highly Active Antiretroviral Therapy
To the Editor-We read with great interest the article by Mariana Lazo et al. [1] regarding factors influencing adherence to HAART. We would like to add to the ongoing adherence debate by describing our own experience, which examines the importance of 1 additional factor, hospitalization [2, 3] at the time of starting HAART. We reviewed data and compared virological success after 12 months of therapy among all HAART-naive patients with no resistance to antiretroviral agents who started HAART while hospitalized with that among patients who started HAART at our outpatient clinic from January 2004 through January 2006. Adherence was assessed through medical outcomes study questionnaires administered to all patients at 6 and 12 months after initiation of therapy and through pharmacy refill data. Twenty-one patients were hospitalized (group 1), and there were 76 outpatients (group 2). Group 1 was composed of 15 men and 6 women; 15 white persons, 5 African black persons, and 1 Indian person; 10 heterosexual persons, 9 men who have sex with men, and 3 injection drug users; the median age was 41.4 years (range, 28-55 years). All 21 patients had AIDS. The mean CD4 cell count at initiation of HAART was 75 cells/mL (range, 10-298 cells/mL), and the mean HIV RNA level was 283,960 copies/mL (range, 3984 to 1500,000 copies/mL). All patients received either zidovudine plus lamivudine or tenofovir plus emtricitabine. Fifteen patients were given a protease inhibitorbased regimen (lopinavir plus ritonavir or fosamprenavir), and 6 were given a nonnucleoside reverse-transcriptase inhibitor-based regimen (2 received nevirapine, and 4 received efavirenz). After discharge from the hospital (mean duration of hospitalization, 24 days), the patients were observed as outpatients.
Group 2 was composed of 40 men and 36 women; 55 white persons and 21 African black persons; and 45 heterosexual persons, 16 men who have sex with men, and 15 previous injection drug users; the median age was 39 years (range, 20-63 years). None of the patients in group 2 had ever experienced serious complications, tumors, or opportunistic infections requiring hospitalization. HAART was started because of low CD4 cell count. The mean CD4 cell count was 220 cells/mL (range, 185-299 cells/mL), and the mean HIV RNA level was 60,615 copies/mL (521-458,109 copies/mL). Thirty-eight patients initiated a nonnucleoside reversetranscriptase inhibitor-based regimen, 28 initiated a protease inhibitor-based regimen, and 10 received a triple nucleoside reverse-transcriptase inhibitor combination.
Results are shown in table 1 and clearly indicate a far better adherence to HAART among initially hospitalized patients that among patients who initiated HAART as outpatients. All initially hospitalized patients achieved undetectable HIV RNA levels 8-36 weeks after initiation of therapy and maintained undetectable levels at 1 year after initation of therapy. In contrast, only 48 outpatients achieved viral
